OncoMatch/Clinical Trials/NCT07629726
A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms
Is NCT07629726 recruiting? Yes, currently enrolling (Jul 2026). This Phase 1/2 trial studies KK2430 for hematologic neoplasms.
Treatment: KK2430 — KK2430 ("Study Drug") as a potential treatment for people with Hematologic Neoplasms. KK2430 is an experimental drug; it has not been approved for the treatment of any disease by health authorities such as United States Food and Drug Administration (FDA), and this is the first time it will be given to people. The purpose of this Study is to find out more information about KK2430, whether it is safe in humans, how the body processes it, and if it works for treating your condition.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: allogenic transplant
History of prior allogenic transplant
Lab requirements
Blood counts
ANC, Platelets, Corrected serum calcium
Kidney function
Renal function values
Liver function
Meet laboratory values at Screening i.e., AST and ALT, Total bilirubin etc
Meet laboratory values at Screening i.e., ANC, Platelets, Corrected serum calcium, AST and ALT, Total bilirubin etc
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Prisma Health · Greenville, South Carolina
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07629726 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogenic transplant disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify